NCT06789913: A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
- State
- Under way
- Phase
- Phase 2
- People
- 277 planned
- Started
- 13 Jun 2025
- Primary completion
- Jul 2031
- Arms
- Part 1, Group 1, Part 1, Group 2, Part 1, Group 3, Part 2, Group 1, Part 2, Group 2, Part 2, Group 3, Part 3, Arm 1
- Results
- None posted
- 23 Jan 2025: Trial registered
- 13 Jun 2025: Trial started